KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. Show more

1167 Massachusetts Avenue, Suite 120, Arlington, MA, 02476, United States

Biotechnology

Healthcare

Market Cap

11.58M

52 Wk Range

$0.49 - $988.50

Previous Close

$0.60

Open

$0.58

Volume

37,996

Day Range

$0.56 - $0.59

Enterprise Value

4.029M

Cash

7.229M

Avg Qtr Burn

-1.535M

Insider Ownership

1.24%

Institutional Own.

4.07%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
INVELTYS™ (loteprednol etabonate ophthalmic suspension) Details Post-operative ocular inflammation and pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EYSUVIS™ (loteprednol etabonate ophthalmic suspension) Details Dry Eye Disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KPI-012 Details Persistent Corneal Epithelial Defect	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.